Evidence map›Paper›PMID 40430474›Full record

ArticlePharmaceuticals (Basel, Switzerland)2025

Development of Rifampicin Eye Drops for the Treatment of Exudative Age-Related Macular Degeneration.

Valory Anne S Vailoces, Andrew J Tolentino, Jose Fernando Arevalo, Ron A Adelman, Robert Bhisitkul, Diana V Do, Quan Dong Nguyen, Michael J Tolentino, Masaki Tanito, Hiroaki Serizawa

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Valory Anne S VailocesSchool of Medicine & Health Sciences, George Washington University, Washington, DC 20052, USA.
Andrew J TolentinoDepartment of Biology, University of California Berkeley, Berkeley, CA 94720, USA.
Jose Fernando ArevaloRetina Division, Wilmer Eye Institute, Department of Ophthalmology at Johns Hopkins Bayview Medical Center, Johns Hopkins University, Baltimore, MD 21287, USA.ORCID 0000-0001-6104-5737
Ron A AdelmanDepartment of Ophthalmology and Visual Science, School of Medicine, Yale University, New Haven, CT 06510, USA.
Robert BhisitkulDepartment of Ophthalmology, University of California San Francisco, San Francisco, CA 94158, USA.
Diana V DoDepartment of Ophthalmology, Byers Eye Institute, School of Medicine, Stanford University, Palo Alto, CA 94303, USA.
Quan Dong NguyenDepartment of Ophthalmology, Byers Eye Institute, School of Medicine, Stanford University, Palo Alto, CA 94303, USA.
Michael J TolentinoDepartment of Ophthalmology, School of Medicine, University of Central Florida, Orlando, FL 32827, USA.ORCID 0000-0003-4914-7356
Masaki TanitoDepartment of Ophthalmology, Shimane University Faculty of Medicine, Shimane 693-8501, Japan.ORCID 0000-0001-6512-7203
Hiroaki SerizawaAMD Therapeutics LLC, Palo Alto, CA 94306, USA.

Funding

AMD Therapeutics LLC N/ANeoVascularX, Inc N/A
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

anti-angiogenesiseye dropsmacular degenerationneovascularizationrifampicinrifamycinVEGF

Identifiers

PMID40430474
PMCPMC12115180

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.